
Last updated: 2026-09-22 21:17:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Kardigan, Inc. (KARD) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $16,49, with a market capitalization of $1,56B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $15,83 to $27,00. This page covers its latest market performance, valuation, price trends and company information.
$1,56B | |
$16,55 | |
$27,00 | |
$15,83 | |
$16,30 | |
361,36K | |
470,10K | |
-- | |
$27,00 | |
$15,83 | |
-- | |
-- |
Kardigan, Inc. (KARD) is trading at $16,51 in after-hours trading as of 2026-09-22 20:55:00, up 1,29% ($0,21) from the regular-session close of $16,30.
After-hours trading shows how investors are pricing KARD after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Kardigan, Inc. (KARD) moved from $18,52 to $16,49, representing a decline of 10,97% ($2,03).
The stock traded between $15,83 and $19,81 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1,51 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 5,9%
KARD is currently trading at $16,49, placing it 5,9% of the way from its 52-week low of $15,83 to its 52-week high of $27,00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Kardigan, Inc. (KARD) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.